What question did this study set out to answer?

The aim is to identify molecular signatures related to early disease clearance in ulcerative colitis patients receiving vedolizumab treatment.

DOP046Molecular and cellular signatures accompanying early disease clearance in Ulcerative Colitis patients treated with vedolizumab in the VERDICT trial

View Full Paper

Ask AI

Bookmark

Authors

Trial reveals gene expression shifts associated with disease clearance in ulcerative colitis, suggesting biomarkers for treatment efficacy.

The aim is to identify molecular signatures related to early disease clearance in ulcerative colitis patients receiving vedolizumab treatment.
Conducted the VERDICT trial comparing treatment approaches for ulcerative colitis.
Collected colonic biopsy samples at baseline and week 16 from patients to analyze gene expression.
Utilized differential gene expression analysis through DESeq2 and pathway analysis using clusterProfiler.
Conducted cell-type enrichment analysis based on data from a human UC single-cell atlas.
Compared to non-remitters, over 10,000 differentially expressed genes were observed in patients who achieved disease clearance at W16.
Disease clearance was associated with downregulation of inflammatory genes and upregulation of immunometabolic genes.
A set of 120 distinct transcriptional modules was identified in patients achieving disease clearance, linked to barrier restoration and fibro-inflammation reduction.

Powell et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark

Trial reveals gene expression shifts associated with disease clearance in ulcerative colitis, suggesting biomarkers for treatment efficacy.